1st Quarter - Report

PARRY, ROMANI, DECONCINI & SYMMS for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Law Enforcement/Crime/Criminal Justice LAW

Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Oppose importation of unsafe drugs from outside the United States. Monitor S. 515, Patent Law Reform. Support amendments to strengthen patent enforcement.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 515 (111th)

Financial Institutions/Investments/Securities FIN

Monitor legislation reforming the Committee on Foreign Investment in the United States process.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Monitor Affordable Biologics for Consumers Act and Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity. H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1956 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.